CalciMedica, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
CalciMedica (NASDAQ:CALC) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $(0.28) by 207.14 percent. This is a 183.33 percent increase over losses of $(0.36) per share from the
FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling studies advancing for...
Oppenheimer analyst Leland Gershell maintains CalciMedica (NASDAQ:CALC) with a Outperform and lowers the price target from $20 to $10.
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the year ended December 31, 2025 and provided clinical and corporate updates.
CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.42) by 65.47 percent. This is a 102.94 percent decrease over losses of $(0.34) per share from
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
The biopharma will now evaluate how it can safely progress Auxora’s development in AKI.
The biopharma will now evaluate how it can safely progress Auxora’s development in AKI.
HC Wainwright & Co. analyst Joseph Pantginis downgrades CalciMedica (NASDAQ:CALC) from Buy to Neutral.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 128.1K | $69.16K | 0.00% | Added+45.0% | 2026-03-31 |
| StateStreet | passive | 17.1K | $9.22K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-12 | -0.28 | 0.30 | +207.14% |
| 2026-03-03 | -0.41 | -0.69 | -67.27% |
| 2025-11-12 | -0.41 | -0.52 | -26.06% |
| 2025-08-12 | -0.35 | -0.40 | -14.29% |
| 2025-05-14 | -0.30 | -0.36 | -20.00% |
| 2025-03-27 | -0.35 | -1.22 | -246.10% |
| 2024-11-13 | -0.50 | -0.50 | -0.67% |
| 2024-08-12 | -0.53 | -0.36 | +31.65% |
| 2024-05-13 | -0.74 | 0.01 | +101.35% |
| 2024-03-28 | -1.00 | -0.23 | +77.00% |
| 2023-11-09 | -1.14 | -0.82 | +28.07% |
| 2023-08-10 | -1.04 | -1.11 | -6.22% |
| 2023-05-12 | -0.73 | -3.41 | -366.66% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CALC | +38.71% | +40.86% | -87.60% | -52.22% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +35.74% | +45.50% | -84.16% | -64.91% |